BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31264396)

  • 1. Clinical use of polyvalent intravenous immunoglobulins during intensive polychemotherapy in children with acute lymphoblastic leukemia.
    Jowik K; Marciniak-Stępak P; Derwich K
    Minerva Pediatr (Torino); 2023 Aug; 75(4):583-589. PubMed ID: 31264396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
    Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
    Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection-related complications during treatment for childhood acute lymphoblastic leukemia.
    Inaba H; Pei D; Wolf J; Howard SC; Hayden RT; Go M; Varechtchouk O; Hahn T; Buaboonnam J; Metzger ML; Rubnitz JE; Ribeiro RC; Sandlund JT; Jeha S; Cheng C; Evans WE; Relling MV; Pui CH
    Ann Oncol; 2017 Feb; 28(2):386-392. PubMed ID: 28426102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic difficulties of AH1N1 influenza infection in children with acute lymphoblastic leukemia: Two case reports.
    Zawitkowska J; Lejman M; Drabko K; Zaucha-Prażmo A
    Medicine (Baltimore); 2020 Oct; 99(43):e22790. PubMed ID: 33120795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
    Glodkowska E; Bialas A; Jackowska T
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective.
    Van Winkle P; Burchette R; Kim R; Raghunathan R; Qureshi N
    Perm J; 2018; 22():17-141. PubMed ID: 29702054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection.
    El-Chennawi FA; Al-Tonbary YA; Mossad YM; Ahmed MA
    Hematology; 2008 Aug; 13(4):203-9. PubMed ID: 18796245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group.
    Ohno R; Tomonaga M; Ohshima T; Masaoka T; Asou N; Oh H; Nishikawa K; Kanamaru A; Murakami H; Furusawa S
    Int J Hematol; 1993 Aug; 58(1-2):73-81. PubMed ID: 7693029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.
    Mungle T; Das N; Pal S; Gogoi MP; Das P; Ghara N; Ghosh D; Arora RS; Bhakta N; Saha V; Krishnan S
    Cancer Med; 2023 Feb; 12(3):3499-3508. PubMed ID: 36812120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
    J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
    Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
    Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
    Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.